The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.
The effective identification and management of type 2 diabetes (T2D) in primary care is a healthcare priority. New antidiabetic agents, including glucagon-like peptide (GLP)-1 receptor agonists, may help overcome drawbacks with current treatments. These new agents have been reviewed in the updated National Institute for Health and Clinical Excellence (NICE) guidelines for the treatment of T2D. Liraglutide, a GLP-1 receptor agonist, was licensed for use in patients with T2D after the development of the NICE guidelines. Data from Phase III trials evaluating liraglutide are presented here in the context of the role of GLP-1 receptor agonists in NICE guidelines.
Gadsby
Roger
R
Warwick Medical School, University of Warwick, Coventry, UK. r.gadsby@warwick.ac.uk
D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005060:Europe; D019317:Evidence-Based Medicine; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical; D016896:Treatment Outcome; D014481:United States
D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1